Insmed Incorporated (INSM)

Market Cap	12.66B
Revenue (ttm)	328.61M
Net Income (ttm)	-802.69M
Shares Out	171.85M
EPS (ttm)	-5.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	803,016
Open	72.02
Previous Close	72.28
Day's Range	72.02 - 74.03
52-Week Range	21.92 - 80.53
Beta	1.11
Analysts	Strong Buy
Price Target	83.29 (+13.04%)
Earnings Date	Oct 31, 2024

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2000
• Employees: 912
• Stock Exchange: NASDAQ
• Ticker Symbol: INSM
• Website: https://www.insmed.com

Financial Performance

In 2023, Insmed's revenue was $305.21 million, an increase of 24.39% compared to the previous year's $245.36 million. Losses were -$749.57 million, 55.7% more than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $83.29, which is an increase of 13.04% from the latest price.

Price Target

$83.29

(13.04% upside)

Analyst Consensus: Strong Buy